2025 Q4 -tulosraportti
Vain PDF
27 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 714 | - | - | ||
| 25 232 | - | - | ||
| 1 500 | - | - | ||
| 2 800 | - | - | ||
| 1 784 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sittenWhy this could explode 🚀 Circio is starting to look very exciting now! * Up to 40–50x improved gene expression in new data * Collaboration with Big Pharma / top 5 pharma feasibility study * Oversubscribed financing of 250 million * Financing that can provide runway towards 2030 This is no longer just a typical Norwegian biotech small-cap stock. If circVec technology continues to deliver strong results, this could develop into a serious international biotech case. The risk is still high, but the upside is starting to become significant.
·3 t sittenCOUNTDOWN TO TOTAL DOMINANCE: BOSTON WEEK IS HERE! 🏁🧬 Hold on tight. What we've been waiting for for months starts NOW. This is not just a conference – it's Circio's global exam, and we already have the answer key. These are the next few days: • TOMORROW (Poster): The first official evidence will be presented. The world will see the technical details that make circVec unique. • MAY 15 (Oral Presentation): This is the premier league. Circio takes the stage to tell Big Pharma face to face why their current gene therapy is outdated. • THE AFTERMATH: When the dust settles in Boston, we will be left with technology validated on the world's biggest stage. Then the phones will start ringing. We're talking in vivo data, circular superiority, and a checkmate position that turns the short to ashes. Those sitting on the fence now will see a completely different price when the weekend rings in. This is the moment where the "Ludo players" are separated from those who understand chess. Enjoy the show. We are set for the history books. We know what we own. ♟️🧱🍷
·5 t sittenBig Pharma's acquisition of Circio? I know many here think one is crazy for bringing up the subject... But, what has really boosted the case already NOW for Circio, a few days before the oral abstract, are Theroma's results in humanized mice. Humanized mice are models where the mice have received human immune cells or tissue, so the results become much more relevant in relation to humans. When a technology shows strong effect in these models, it suddenly becomes something Big Pharma takes very seriously, because the probability of clinical success is considered higher. Theroma's data also shows that circRNA functions in more complex biological environments and not just under simple laboratory conditions. This is important because it supports the whole idea that circVec from Circio can be used broadly in both gene therapy and cell therapy. With 60x stronger protein expression and very high efficacy at minimal dose, it really ticks many boxes for solutions to known problems with mRNA. Not to mention the possibilities in all vaccines, which PT primarily uses mRNA technology. With Circio's current data, everyone and all competitors are completely blown away. Remember that Circio's feasibility study with the secret Big Pharma has progressed to in vivo studies. This only happens if the partner is satisfied with the initial results. Is it Eli Lilly?, Roche?, Johnson & Johnson? or AstraZeneca? They all have such deep pockets that it seems unrealistic for us normal people. That particular big pharma will 100% open the bidding round. It's not Circio that will run the validation in humans, Big Pharma will do that themselves. If you have the money to buy the fastest racehorse, it's clearly advantageous to fly over the finish line yourself as the winner. Acquisition after ASGCT could come faster than we think. Just look at ORNA Therapeutics which was at a preclinical stage, even with ordinary conventional technology. 6-8-10 billion dollars for a nextgen platform that totally replaces mRNA? The market is gigantic. I think that's a low estimate. 💰
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
27 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenWhy this could explode 🚀 Circio is starting to look very exciting now! * Up to 40–50x improved gene expression in new data * Collaboration with Big Pharma / top 5 pharma feasibility study * Oversubscribed financing of 250 million * Financing that can provide runway towards 2030 This is no longer just a typical Norwegian biotech small-cap stock. If circVec technology continues to deliver strong results, this could develop into a serious international biotech case. The risk is still high, but the upside is starting to become significant.
- ·3 t sittenCOUNTDOWN TO TOTAL DOMINANCE: BOSTON WEEK IS HERE! 🏁🧬 Hold on tight. What we've been waiting for for months starts NOW. This is not just a conference – it's Circio's global exam, and we already have the answer key. These are the next few days: • TOMORROW (Poster): The first official evidence will be presented. The world will see the technical details that make circVec unique. • MAY 15 (Oral Presentation): This is the premier league. Circio takes the stage to tell Big Pharma face to face why their current gene therapy is outdated. • THE AFTERMATH: When the dust settles in Boston, we will be left with technology validated on the world's biggest stage. Then the phones will start ringing. We're talking in vivo data, circular superiority, and a checkmate position that turns the short to ashes. Those sitting on the fence now will see a completely different price when the weekend rings in. This is the moment where the "Ludo players" are separated from those who understand chess. Enjoy the show. We are set for the history books. We know what we own. ♟️🧱🍷
- ·5 t sittenBig Pharma's acquisition of Circio? I know many here think one is crazy for bringing up the subject... But, what has really boosted the case already NOW for Circio, a few days before the oral abstract, are Theroma's results in humanized mice. Humanized mice are models where the mice have received human immune cells or tissue, so the results become much more relevant in relation to humans. When a technology shows strong effect in these models, it suddenly becomes something Big Pharma takes very seriously, because the probability of clinical success is considered higher. Theroma's data also shows that circRNA functions in more complex biological environments and not just under simple laboratory conditions. This is important because it supports the whole idea that circVec from Circio can be used broadly in both gene therapy and cell therapy. With 60x stronger protein expression and very high efficacy at minimal dose, it really ticks many boxes for solutions to known problems with mRNA. Not to mention the possibilities in all vaccines, which PT primarily uses mRNA technology. With Circio's current data, everyone and all competitors are completely blown away. Remember that Circio's feasibility study with the secret Big Pharma has progressed to in vivo studies. This only happens if the partner is satisfied with the initial results. Is it Eli Lilly?, Roche?, Johnson & Johnson? or AstraZeneca? They all have such deep pockets that it seems unrealistic for us normal people. That particular big pharma will 100% open the bidding round. It's not Circio that will run the validation in humans, Big Pharma will do that themselves. If you have the money to buy the fastest racehorse, it's clearly advantageous to fly over the finish line yourself as the winner. Acquisition after ASGCT could come faster than we think. Just look at ORNA Therapeutics which was at a preclinical stage, even with ordinary conventional technology. 6-8-10 billion dollars for a nextgen platform that totally replaces mRNA? The market is gigantic. I think that's a low estimate. 💰
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 714 | - | - | ||
| 25 232 | - | - | ||
| 1 500 | - | - | ||
| 2 800 | - | - | ||
| 1 784 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
27 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenWhy this could explode 🚀 Circio is starting to look very exciting now! * Up to 40–50x improved gene expression in new data * Collaboration with Big Pharma / top 5 pharma feasibility study * Oversubscribed financing of 250 million * Financing that can provide runway towards 2030 This is no longer just a typical Norwegian biotech small-cap stock. If circVec technology continues to deliver strong results, this could develop into a serious international biotech case. The risk is still high, but the upside is starting to become significant.
- ·3 t sittenCOUNTDOWN TO TOTAL DOMINANCE: BOSTON WEEK IS HERE! 🏁🧬 Hold on tight. What we've been waiting for for months starts NOW. This is not just a conference – it's Circio's global exam, and we already have the answer key. These are the next few days: • TOMORROW (Poster): The first official evidence will be presented. The world will see the technical details that make circVec unique. • MAY 15 (Oral Presentation): This is the premier league. Circio takes the stage to tell Big Pharma face to face why their current gene therapy is outdated. • THE AFTERMATH: When the dust settles in Boston, we will be left with technology validated on the world's biggest stage. Then the phones will start ringing. We're talking in vivo data, circular superiority, and a checkmate position that turns the short to ashes. Those sitting on the fence now will see a completely different price when the weekend rings in. This is the moment where the "Ludo players" are separated from those who understand chess. Enjoy the show. We are set for the history books. We know what we own. ♟️🧱🍷
- ·5 t sittenBig Pharma's acquisition of Circio? I know many here think one is crazy for bringing up the subject... But, what has really boosted the case already NOW for Circio, a few days before the oral abstract, are Theroma's results in humanized mice. Humanized mice are models where the mice have received human immune cells or tissue, so the results become much more relevant in relation to humans. When a technology shows strong effect in these models, it suddenly becomes something Big Pharma takes very seriously, because the probability of clinical success is considered higher. Theroma's data also shows that circRNA functions in more complex biological environments and not just under simple laboratory conditions. This is important because it supports the whole idea that circVec from Circio can be used broadly in both gene therapy and cell therapy. With 60x stronger protein expression and very high efficacy at minimal dose, it really ticks many boxes for solutions to known problems with mRNA. Not to mention the possibilities in all vaccines, which PT primarily uses mRNA technology. With Circio's current data, everyone and all competitors are completely blown away. Remember that Circio's feasibility study with the secret Big Pharma has progressed to in vivo studies. This only happens if the partner is satisfied with the initial results. Is it Eli Lilly?, Roche?, Johnson & Johnson? or AstraZeneca? They all have such deep pockets that it seems unrealistic for us normal people. That particular big pharma will 100% open the bidding round. It's not Circio that will run the validation in humans, Big Pharma will do that themselves. If you have the money to buy the fastest racehorse, it's clearly advantageous to fly over the finish line yourself as the winner. Acquisition after ASGCT could come faster than we think. Just look at ORNA Therapeutics which was at a preclinical stage, even with ordinary conventional technology. 6-8-10 billion dollars for a nextgen platform that totally replaces mRNA? The market is gigantic. I think that's a low estimate. 💰
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 714 | - | - | ||
| 25 232 | - | - | ||
| 1 500 | - | - | ||
| 2 800 | - | - | ||
| 1 784 | - | - |
Välittäjätilasto
Dataa ei löytynyt